Olaparib combined with BKM120 (later copanlisib) inhibited tumor growth in PTEN-/TP53-deficient prostate cancer cell lines and PTEN wild-type/TP53-deleted prostate cancer xenografts (17). Here, PTEN is linked to neoplasm.